Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS8807 in advanced breast cancer
NCT04993430Phase 1Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS8807 in breast cancer (4 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
HRS8807
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04993430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993430.